Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?

被引：6
|
作者：
Munir, Kashif M. [1 ]
Davis, Stephen N. [2 ]
机构：
[1] Univ Maryland, Sch Med, Ctr Diabet & Endocrinol, Div Endocrinol Diabet & Nutr, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Med, 22 South Greene St, Baltimore, MD 21201 USA
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2018年 / 19卷 / 08期
关键词：
GLP-1 receptor agonist; SGLT2; inhibitor; type; 2; diabetes; cardiovascular outcomes; GLUCOSE-LOWERING DRUGS; CARDIOVASCULAR OUTCOMES; CVD-REAL; MORTALITY; EMPAGLIFLOZIN; LIRAGLUTIDE;
D O I：
10.1080/14656566.2018.1475559
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：773 / 777
页数：5
相关论文
共 50 条
  • [1] SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
    Gurgle, Holly E.
    White, Karen
    McAdam-Marx, Carrie
    VASCULAR HEALTH AND RISK MANAGEMENT, 2016, 12 : 239 - 249
  • [2] Type 1 diabetes: Prescription of GLP-1 receptor agonists and SGLT2 inhibitors
    Simon, Annika
    DIABETOLOGIE UND STOFFWECHSEL, 2025, 20 (01) : 23 - 23
  • [3] Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2019, 61 (1566): : 26 - 28
  • [4] Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes
    Neuen, Brendon L.
    Solomon, Scott D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (08) : 709 - 711
  • [5] Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
    Nagahisa, Taichi
    Saisho, Yoshifumi
    DIABETES THERAPY, 2019, 10 (05) : 1733 - 1752
  • [6] SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Shaughnessy, Allen F.
    AMERICAN FAMILY PHYSICIAN, 2021, 104 (02) : 206 - 206
  • [7] Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
    Taichi Nagahisa
    Yoshifumi Saisho
    Diabetes Therapy, 2019, 10 : 1733 - 1752
  • [8] Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes
    Edmonston, Daniel
    Mulder, Hillary
    Lydon, Elizabeth
    Chiswell, Karen
    Lampron, Zachary
    Shay, Christina
    Marsolo, Keith
    Shah, Raj C.
    Jones, W. Schuyler
    Gordon, Howard
    Hwang, Wenke
    Ayoub, Isabella
    Ford, Daniel
    Chamberlain, Alanna
    Rao, Ajaykumar
    Fonseca, Vivian
    Chang, Alexander
    Ahmad, Faraz
    Hung, Adriana
    Hunt, Kelly
    Butler, Javed
    Bosworth, Hayden B.
    Pagidipati, Neha
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (08) : 696 - 708
  • [9] Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
    Rodriguez, Luis A.
    Finertie, Holly
    Neugebauer, Romain S.
    Gosiker, Bennett
    Thomas, Tainayah W.
    Karter, Andrew J.
    Gilliam, Lisa K.
    Oshiro, Caryn
    An, Jaejin
    Simonson, Gregg
    Cassidy-Bushrow, Andrea E.
    Dombrowski, Sarah
    Nolan, Margaret
    O'Connor, Patrick J.
    Schmittdiel, Julie A.
    LANCET REGIONAL HEALTH-AMERICAS, 2024, 34
  • [10] SGLT-2 inhibitors and GLP-1 receptor agonists for Type 2 diabetes
    Davila, Esteban
    Mccormack, James
    ACADEMIC EMERGENCY MEDICINE, 2024, 31 (04) : 408 - 411
12345